TELA Bio IncNASDAQ:TELA
- LAST PRICE9.8700
- TODAY'S CHANGE (%)-0.6200 (-5.9104%)
- Bid / Lots7.5000/ 1
- Ask / Lots10.4600/ 1
- Open / Previous Close10.5000 / 10.4900
- Day Range
- 52 Week Range
- Volume31,340
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TELA |
|---|---|---|
| 09:32 ET | 738 | 10.5 |
| 09:36 ET | 100 | 10.4699 |
| 09:38 ET | 335 | 10.4 |
| 09:41 ET | 200 | 10.36 |
| 09:43 ET | 100 | 10.37 |
| 09:45 ET | 100 | 10.35 |
| 09:48 ET | 200 | 10.305 |
| 09:50 ET | 300 | 10.27 |
| 09:52 ET | 200 | 10.21 |
| 09:54 ET | 340 | 10.2 |
| 09:56 ET | 200 | 9.925 |
| 09:57 ET | 200 | 10.035 |
| 09:59 ET | 200 | 9.895 |
| 10:01 ET | 100 | 9.89 |
| 10:03 ET | 100 | 9.89 |
| 10:06 ET | 200 | 9.88 |
| 10:08 ET | 300 | 9.88 |
| 10:10 ET | 100 | 9.89 |
| 10:12 ET | 220 | 9.88 |
| 10:26 ET | 300 | 9.885 |
| 10:33 ET | 700 | 9.77 |
| 10:37 ET | 100 | 9.78 |
| 10:46 ET | 300 | 9.8938 |
| 10:50 ET | 1460 | 9.552 |
| 10:51 ET | 300 | 9.675 |
| 10:55 ET | 300 | 9.735 |
| 10:57 ET | 170 | 9.6276 |
| 11:06 ET | 3200 | 10.06 |
| 11:08 ET | 3162 | 9.995 |
| 11:09 ET | 200 | 10 |
| 11:24 ET | 100 | 10 |
| 11:29 ET | 200 | 10 |
| 11:38 ET | 100 | 10 |
| 12:23 ET | 100 | 9.935 |
| 12:27 ET | 530 | 10 |
| 12:30 ET | 779 | 10 |
| 01:33 ET | 100 | 9.99 |
| 01:44 ET | 100 | 9.99 |
| 01:57 ET | 200 | 9.92 |
| 02:04 ET | 100 | 9.91 |
| 02:09 ET | 100 | 9.93 |
| 02:45 ET | 100 | 9.87 |
| 03:05 ET | 400 | 9.76 |
| 03:39 ET | 311 | 9.91 |
| 03:50 ET | 100 | 9.8 |
| 03:52 ET | 100 | 9.89 |
| 03:59 ET | 997 | 9.87 |
Yesterday
Tela Bio Narrows Q4 Net Loss, Revenue Rises, from 4:31PM ET on Tuesday Mar 21, 2023 by MT Newswires
4:31PM ET on Tuesday Mar 21, 2023 by MT Newswires--TELA Bio Guides For Full Year 2023 Revenue of $60-$65 Million, vs CIQ Analyst Consensus of $60 Million, from 4:04PM ET on Tuesday Mar 21, 2023 by MT Newswires
4:04PM ET on Tuesday Mar 21, 2023 by MT NewswiresBRIEF-Tela Bio Reports Fourth Quarter Results, from 4:04PM ET on Tuesday Mar 21, 2023 by Thomson Reuters
4:04PM ET on Tuesday Mar 21, 2023 by Thomson Reuters-- Earnings Flash (TELA) TELA BIO Reports Q4 Revenue $11.6M, vs. Street Est of $13.2M, from 4:02PM ET on Tuesday Mar 21, 2023 by MT Newswires
4:02PM ET on Tuesday Mar 21, 2023 by MT NewswiresTELA Bio Reports Fourth Quarter and Full Year 2022 Financial Results, from 4:02PM ET on Tuesday Mar 21, 2023 by GlobeNewswire
4:02PM ET on Tuesday Mar 21, 2023 by GlobeNewswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
TELA Bio Inc | 201.0M | -3.5x | --- |
CVRx Inc | 195.9M | -4.6x | --- |
KORU Medical Systems Inc | 176.6M | -20.3x | --- |
Perspective Therapeutics Inc | 187.6M | -8.8x | --- |
Beyond Air Inc | 204.5M | -3.6x | --- |
Semler Scientific Inc | 149.9M | 16.1x | --- |
Company Information
TELA Bio Inc. is a medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. The Company's first portfolio of solutions offers four configurations of the OviTex Reinforced Tissue Matrix (OviTex) designed for hernia repair and abdominal wall reconstruction by combining the benefits of biologic matrices and polymer materials. The Company's OviTex products include OviTex 1S, OviTex 2S, and OviTex LPR. The OviTex products are sterile reinforced tissue matrices derived from ovine rumen with either polypropylene or polyglycolic acid (PGA). The Company's second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
Contact Information
- Headquarters
- 1 Great Valley Parkway, Suite 24MALVERN, PA, United States 19355
- Phone
- 484-320-2930
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Douglas Evans
- President, Chief Executive Officer, Co-Founder, Director
- Antony Koblish
- Chief Financial Officer, Chief Operating Officer, Secretary
- Roberto Cuca
- Chief Commercial Officer
- Peter Murphy
- Chief Strategic Officer
- Paul Talmo
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $201.0M |
|---|---|
Revenue (TTM) | $41.4M |
Shares Outstanding | 19.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.98 |
EPS | $-2.78 |
Book Value | $0.75 |
P/E Ratio | -3.5x |
Price/Sales (TTM) | 4.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -97.14% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
